Aug 05, 2021 08:23 PM (GMT+8) · EqualOcean
HISCO announced that Sichuan HISCO Pharmaceutical Co., Ltd. ("Sichuan HISCO"), a wholly-owned subsidiary of the company, increased the capital of its wholly-owned subsidiary haisco Holdings Pte.Ltd. ("HISCO Holdings") by RMB 142.6 million with its own funds. Haisight Holdings Pte.Ltd. ("hisset Holdings") an affiliated company of the company increased the capital of HISCO Cayman company by RMB 35.658 million with its own funds. HISCO Cayman increased its wholly-owned subsidiary haisco pharmaceutical Pte.Ltd. ("HISCO Pharmaceutical Co., Ltd.") by RMB 17829 million with its own funds. The capital increase will be used for HISCO Pharmaceutical Co., Ltd. to purchase the proprietary technology ownership of some innovative drugs in markets outside mainland China (including Hong Kong, Macao and Taiwan), which will help the company's innovative drugs in overseas clinical trials and listing operations.